Harnessing the hERG1/β1 Integrin Complex via a Novel Bispecific Single-chain Antibody: An Effective Strategy against Solid Cancers

mAbs, either mono- or bispecific (bsAb), represent one of the most successful approaches to treat many types of malignancies. However, there are certain limitations to the use of full length mAbs for clinical applications, which can be overcome by engineered antibody fragments. The aim of this study...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Molecular cancer therapeutics 2021-08, Vol.20 (8), p.1338-1349
Hauptverfasser:	Duranti, Claudia, Iorio, Jessica, Lottini, Tiziano, Lastraioli, Elena, Crescioli, Silvia, Bagni, Giacomo, Lulli, Matteo, Capitani, Chiara, Bouazzi, Rayhana, Stefanini, Matteo, Carraresi, Laura, Iamele, Luisa, De Jonge, Hugo, Arcangeli, Annarosa
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antibodies, Bispecific - pharmacology Apoptosis Cell Movement Cell Proliferation Colonic Neoplasms - drug therapy Colonic Neoplasms - metabolism Colonic Neoplasms - pathology Ether-A-Go-Go Potassium Channels - genetics Ether-A-Go-Go Potassium Channels - metabolism Female Humans Integrin beta1 - genetics Integrin beta1 - metabolism Mice Mice, Nude Neovascularization, Pathologic - drug therapy Neovascularization, Pathologic - metabolism Neovascularization, Pathologic - pathology Pancreatic Neoplasms - drug therapy Pancreatic Neoplasms - metabolism Pancreatic Neoplasms - pathology Protein Binding Single-Chain Antibodies - pharmacology Tumor Cells, Cultured Xenograft Model Antitumor Assays
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!